ArticleThe journal of obstetrics and gynaecology research2025
Co-mutation of PCLO and SYNE1 defines an immune-activated endometrial cancer subtype with favorable prognosis.
Article in The journal of obstetrics and gynaecology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic insights into lung squamous cell carcinoma: howTranslational cancer research · 2026Article
- Co-mutation of PCLO and SYNE1 defines an immune-activated endometrial cancer subtype with favorable prognosis.The journal of obstetrics and gynaecology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEndometrial cancer (EC) is a genomically heterogeneous malignancy with diverse immune microenvironment profiles. Although POLE mutations and MSI-H status are established predictors of immunotherapy response, additional composite biomarkers that integrate mutational burden and immune activation are needed. PCLO and SYNE1 are frequently mutated structural genes in EC, yet their cooperative significance remains unknown.
methodsWe analyzed 505 EC cases from The Cancer Genome Atlas (TCGA) and 95 additional samples from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), stratifying tumors based on PCLO and SYNE1 mutation status. Genomic, transcriptomic, immunologic, and clinical features were compared between co-mutation and non-co-mutation groups. Differential expression gene and pathway enrichment were conducted to identify immune-related transcriptional programs. Survival analysis and nomogram were performed to assess prognostic impact.
resultsPCLO and SYNE1 co-mutation defined a notable EC subtype with significant enrichment of POLE mutations, high tumor mutation burden (TMB), reduced aneuploidy, and elevated MSIsensor scores. Clinically, the overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) of the co-mutation group was significantly improved. Moreover, the co-mutation group exhibited increased infiltration of CD8
conclusionsPCLO and SYNE1 co-mutation identifies a biologically distinct EC subset with heightened immunogenicity and superior prognosis. The co-mutation may serve as a robust, integrative biomarker for immune responsiveness and risk stratification in EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.